Kinathera is a seed stage preclinical biotech on a mission to develop unique series of newly patented, orally delivered small chemical molecules to treat patients suffering from immuno-inflammatory disorders.
Selective inhibition of our most advanced target, simultaneously:
1, blocks intracellular cascade of the ICOS receptor which control maturation of the humoral response and
2, inhibits type 1 interferon production, a master regulator of BAFF expression and demonstrated component of auto-immune diseases.
Activity of Kinathera’s compound on two key immune paths promises enhanced control of hyperactive immune reaction in auto immune or GvHD indications.
Company Details
- Founded
- 2015
- Address
- 163, Avenue De Luminy, Luminy Biotech Entreprises,bâtiment Beret-Delaage,case 922,france
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- balmestransplantation.com
- Keywords
- Organ Transplantation, Drug Development, Acute Kidney Injury (AKI), Autoimmune, Sjoegren's syndrome, Dermatomyositis, Systemic scleroderma, Interferonopathies, GvHD.
- HQ
- Marseille, PACA
Kinathera Questions
Kinathera's website is balmestransplantation.com
Kinathera's LinkedIn profile is https://fr.linkedin.com/company/kinathera
Kinathera's industry is
Pharmaceutical Manufacturing
Kinathera's top competitors are
Oz Biosciences,
Ipsomel,
Innate Pharma,
Genoscience Pharma,
Diamidex,
Provepharm,
Biocellvia,
Imcheck Therapeutics,
Ipsomedic,
Laphal Industries.
Kinathera's categories are Pharmaceutical Manufacturing
Kinathera's founding year is 2015
